AU Health partners with Inflo Health to elevate the radiology follow-up process to optimize the patient experience

CONTACT: Lisa Kaylor, AU Health, 706-755-3160, lkaylor@augusta.edu; Alicia Laszewski, Inflo Health, 954-683-7189, alicia@yourbrandethos.com

AUGUSTA, Ga. (June 13, 2023) – Augusta University Health(AU Health), a comprehensive primary, specialty, and subspeciality healthcare network based in Augusta, Georgia, that serves as the primary teaching affiliate for the Medical College of Georgia, announced today that they are partnering with Inflo Health, a radiology follow-up solution powered by advanced AI and natural language understanding (NLU). Augusta University Health will leverage Inflo Health’s innovative solution to automate the radiology follow-up process for hundreds of thousands of their radiology patients per year.

According to an American College of Radiology study, 60% of radiology imaging follow-ups never get completed. Inflo Health estimates that their platform allows their customers the ability to recapture at least 80% of these missed follow-ups.

“The radiology follow-up process can be challenging and time intensive, with life-changing consequences,” added John Crossgrove, Director of Radiology Services at AU Health. “Inflo Health is a smart and powerful technology that stood out to us during our search for a partner in this area for a multitude of reasons. The ability to automate and close the communication loop with 100% of our providers and patients in this area, across all modalities, without adding additional staff is transformational in supporting our world-class patient care mission and objectives.”

Inflo Health will support all areas within AU Health’s radiology program, including support to close any gaps within the incidental findings program. According to the ACR, incidental findings are defined as “an incidentally discovered mass or lesion, detected by CT, MRI, or other imaging modality performed for an unrelated reason.” Many different forms of cancers are discovered incidentally, and lifesaving therapies can be prescribed much earlier in the tumor development, leading to better patient outcomes.

Dr. Annette Johnson, AU Health’s Chair of Radiology and Imaging commented, “Complexity within health systems contributes to the reality that communication breakdowns are responsible for the majority of safety events in health care environments.  Test results management is a particularly substantial challenge for physicians and other providers, despite their diligence and focused efforts at information management.  Breakdowns in communication of test results occur across the spectrum of clinical settings and can result in delayed diagnoses and harm to patients. Our vision in AU Health Radiology is ‘Better imaging for better health.’ By partnering with Inflo Health, we can further this vision by creating automated processes for identification and tracking of imaging findings that require follow-up—so that we can have a failsafe system for providing timely and potentially life-saving testing and treatment to further ensure the delivery of the very best care for our patients. We are thrilled to have selected Inflo Health as our partner on this journey.”

Angela Adams, CEO of Inflo Health, said, “A recent article published by the American College of Radiology (ACR) cited that over 65% of Emergency Physicians and Radiologists report that their health systems do not have a tracking mechanism for incidental findings today. This is a staggering statistic given the importance of timely identification and communication for healthy patient outcomes. Augusta University Health is an innovative health system, and we are proud to partner with them on this mission-critical enhancement to their radiology team and their patients.” 

Inflo Health was founded by a revolutionary radiologist, frustrated by an overworked and inefficient healthcare system, who wanted to improve the patient outcomes. As a result, a team of clinical and technical experts came together to develop large language models and NLU to read and understand radiology reports with the goal of automating identification of which patients have recommendations for additional imaging. Inflo Health then automates communication to the care team and to the patients to help ensure the follow-ups are ordered and scheduled. The Inflo Health platform streamlines the management of radiology follow-up recommendations across all imaging modalities.

About Inflo Health: We harness the power of advanced AI, large language models, and NLU to turn radiology follow-up into a stress-free process. Our proven, automated solution streamlines the management of follow-up recommendations across all imaging modalities, so you can ensure no patient falls through the care gap. With our easy-to-use, integrated platform, your team can focus on delivering top-quality patient care, while also mitigating risk, and maximizing staff efficiency.

###

AU Health is Georgia’s only public academic health center, where world-class clinicians are bringing the medicine of tomorrow to patient care today. As the primary teaching affiliate of the Medical College of Georgia, AU Health provides the most comprehensive routine-to-complex care at AU Medical Center, which houses the region’s only Level 1 trauma center, as well as Children’s Hospital of Georgia, Georgia Cancer Center, historic Roosevelt Warm Springs Rehabilitation and Specialty Hospitals, Georgia War Veterans Nursing Home, and more than 100 primary and specialty care clinics across the state.

Georgia Life Sciences Weighs In on PBM and 340B Policy

October 5, 2026
Georgia Life Sciences has submitted written comments to the Georgia House Study Committee on Pharmacy Benefits Managers and Consumers’ Access to Prescription Medications, encouraging greater transparency, accountability, and a focus on measurable patient benefit across the prescription drug system. The comments address both pharmacy benefit manager practices and the federal 340B Drug Pricing Program, emphasizing the importance of understanding where prescription drug savings accrue and whether those savings ultimately benefit patients. The Study Committee continues its work this fall as it develops recommendations for the Georgia General Assembly. Read Georgia Life Sciences’ full comments →

Georgia Life Sciences Joins National Coalition Calling for PAHPA Reauthorization

September 22, 2026
Georgia Life Sciences (GLS) has joined more than 80 organizations from across industry, academia, public health and the biosecurity community in calling on congressional leaders to fully reauthorize the Pandemic and All-Hazards Preparedness Act (PAHPA) before the end of 2026. Led by the Johns Hopkins Center for Health Security, the coalition urged congressional leaders to advance a comprehensive reauthorization of PAHPA, the federal framework that supports the nation’s ability to prepare for and respond to public health emergencies and other health security threats. First enacted in 2006, PAHPA established and strengthened critical components of the nation’s health security infrastructure, including the Biomedical Advanced Research and Development Authority (BARDA). The law also supports public-private partnerships involved in the research, development, manufacturing and procurement of medical countermeasures, including vaccines, therapeutics and diagnostics. PAHPA’s authorization expired in 2023 and key provisions have since continued through short-term extensions. The coalition is calling for a comprehensive reauthorization that provides greater stability and ensures the nation’s preparedness infrastructure can continue adapting to emerging biological, infectious disease and other health security threats. For the life sciences industry, these programs are particularly important. Partnerships between government and industry can help move promising technologies from research through development and manufacturing while maintaining capabilities needed to respond quickly during an emergency. The Biotechnology Innovation Organization (BIO), also a signatory to the letter, has identified several priorities for reauthorization, including continued authorization of BARDA, the Strategic National Stockpile, Project BioShield and the Pandemic Influenza Program, as well as incentives supporting the development of medical countermeasures. Georgia Life Sciences is proud to join organizations across the country in supporting a strong and sustainable national framework for health security, preparedness and biomedical innovation. Read the coalition letter and view the full list of signatories.

Georgia Life Sciences Urges Protection of Patient Access as Georgia Implements Medicaid Changes

September 14, 2026
Georgia Life Sciences has submitted comments to the Georgia Department of Community Health (DCH) regarding the Georgia Pathways to Coverage program and implementation of new federal Medicaid requirements. As Georgia prepares for these changes, Georgia Life Sciences is urging state leaders to prioritize continuity of care and minimize unnecessary administrative barriers that could delay or disrupt access to medically necessary treatment . This is particularly important for Georgians living with serious, chronic, rare, and medically complex conditions who may rely on ongoing medications, diagnostics, therapies, medical technologies, specialty care, and coordinated treatment plans. Even temporary disruptions in coverage can interrupt care and create additional challenges for patients and families. In its comments, Georgia Life Sciences encouraged DCH to protect continuity of coverage during eligibility and redetermination processes, provide patients and caregivers with clear and timely information, minimize unnecessary administrative burdens, and establish appropriate safeguards when a coverage disruption could interrupt an established course of treatment. “As Georgia implements these new federal requirements, we want to ensure that patients remain at the center of the process,” said Maria Thacker Goethe, MPH, President & CEO of Georgia Life Sciences. “Administrative changes should not become barriers between patients and the care they need. Protecting continuity of care is particularly important for Georgians managing serious and complex health conditions.” Read Georgia Life Sciences’ full comments to DCH here.
MORE POSTS